Healthcare provider profile · identity verified

Shreena Dhawan, MD

Allopathic & Osteopathic Physicians|Family Medicine · INDIANAPOLIS, IN · NPI 1932766276

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Shreena Dhawan, MD received $13.50 in general payments during 2025 across 1 reported records.

Exact Sciences Corporation accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$13.50

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Exact Sciences Corporation Unresolved — no canonical attribution shown $13.50100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$13.501

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
The Cologuard Plus Collection Kit
Normalized: the cologuard plus collection kit
Device Exact Sciences Corporation $13.50 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium327102
Levothyroxine SodiumLevothyroxine Sodium22762
Amlodipine BesylateAmlodipine Besylate17756
LisinoprilLisinopril17756
OmeprazoleOmeprazole14945
Losartan PotassiumLosartan Potassium13238
Metoprolol SuccinateMetoprolol Succinate9628
Albuterol Sulfate HfaAlbuterol Sulfate9038
Rosuvastatin CalciumRosuvastatin Calcium9025
Sertraline HclSertraline Hcl7924
Trazodone HclTrazodone Hcl7427
GabapentinGabapentin6921
Metformin HclMetformin Hcl6924
Pantoprazole SodiumPantoprazole Sodium6824
AlprazolamAlprazolam6619
Escitalopram OxalateEscitalopram Oxalate6220
FamotidineFamotidine6219
HydrochlorothiazideHydrochlorothiazide6220
OzempicSemaglutide6211
Metformin Hcl ErMetformin Hcl6120
SimvastatinSimvastatin5718
Bupropion XlBupropion Hcl5415
Fluoxetine HclFluoxetine Hcl4917
Tamsulosin HclTamsulosin Hcl4818
MeloxicamMeloxicam4618
Montelukast SodiumMontelukast Sodium4614
Pravastatin SodiumPravastatin Sodium4513
Cyclobenzaprine HclCyclobenzaprine Hcl4117
Sumatriptan SuccinateSumatriptan Succinate41suppressed
Duloxetine HclDuloxetine Hcl4012
SynthroidLevothyroxine Sodium4011
CarvedilolCarvedilol3912
Hydroxyzine HclHydroxyzine Hcl39suppressed
FurosemideFurosemide3812
GlimepirideGlimepiride3712
Fluticasone PropionateFluticasone Propionate3515
AtenololAtenolol34suppressed
Zolpidem TartrateZolpidem Tartrate33suppressed
Citalopram HbrCitalopram Hydrobromide3111
Potassium ChloridePotassium Chloride31suppressed
PregabalinPregabalin30suppressed
EzetimibeEzetimibe28suppressed
AmoxicillinAmoxicillin2721
MethylprednisoloneMethylprednisolone2722
Metoprolol TartrateMetoprolol Tartrate2711
Doxycycline MonohydrateDoxycycline Monohydrate2624
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25suppressed
MethocarbamolMethocarbamol25suppressed
Alendronate SodiumAlendronate Sodium24suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide24suppressed
MounjaroTirzepatide24suppressed
LovastatinLovastatin23suppressed
Donepezil HclDonepezil Hcl22suppressed
ClopidogrelClopidogrel Bisulfate21suppressed
AllopurinolAllopurinol20suppressed
ClonazepamClonazepam20suppressed
Pioglitazone HclPioglitazone Hcl20suppressed
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid20suppressed
EliquisApixaban19suppressed
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19suppressed
PrednisonePrednisone1916
MirtazapineMirtazapine18suppressed
ValacyclovirValacyclovir Hcl18suppressed
FinasterideFinasteride17suppressed
Levocetirizine DihydrochlorideLevocetirizine Dihydrochloride17suppressed
Diclofenac SodiumDiclofenac Sodium16suppressed
Enalapril MaleateEnalapril Maleate16suppressed
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide16suppressed
Ondansetron OdtOndansetron16suppressed
Glipizide ErGlipizide15suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst1513
Hydralazine HclHydralazine Hcl14suppressed
Ondansetron HclOndansetron Hcl14suppressed
Paroxetine HclParoxetine Hcl14suppressed
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13suppressed
Hydroxyzine PamoateHydroxyzine Pamoate13suppressed
NystatinNystatin13suppressed
Tizanidine HclTizanidine Hcl13suppressed
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13suppressed
Venlafaxine Hcl ErVenlafaxine Hcl13suppressed
FluconazoleFluconazole12suppressed
Tramadol HclTramadol Hcl12suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1111
Esomeprazole MagnesiumEsomeprazole Magnesium11suppressed
Folic AcidFolic Acid11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $13.50 · 1 records Exact Sciences Corporation The Cologuard Plus Collection Kit
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error